A progressive insulin resistant state develops throughout human pregnancy. Inositol phosphoglycan P-type (P-IPG), a second messenger of insulin, was reported to negatively correlate with the degree of insulin resistance in non-pregnant diabetic subjects. Urinary levels of P-IPG were assessed in insulin resistant states during pregnancy such as gestational diabetes mellitus (GDM, ns44) and type 2 diabetes mellitus (type 2 DM, ns25) and in 69 normal pregnant women. Urinary levels of P-IPG were higher in GDM than controls with a positive trend of release throughout normal pregnancy (P-0.01). P-IPG excretion was higher in diabetic (GDM and type 2 DM) than in healthy women in the second trimester (P-0.05). A higher P-IPG urinary excretion occurs during the second trimester in pregnant women with clinically evident insulin resistance with a positive association with poor glycemic control. Inositol phosphoglycan P-type (P-IPG) was highly expressed in normal human pregnancy with a further increase during preeclampsia w4, 5x, a complication of pregnancy characterized by insulin resistance. P-IPG belongs to a family of phospholipid-derived second messengers of insulin that can stimulate glucose and lipid metabolism. These molecules seem to be involved in the pathophysiology of insulin resistance w1x.
Inositol phosphoglycan P-type (P-IPG) was highly expressed in normal human pregnancy with a further increase during preeclampsia w4, 5x, a complication of pregnancy characterized by insulin resistance. P-IPG belongs to a family of phospholipid-derived second messengers of insulin that can stimulate glucose and lipid metabolism. These molecules seem to be involved in the pathophysiology of insulin resistance w1x.
A case-control pilot study was carried out to assess the role of P-IPG in clinically evident insulin resistant states during pregnancy such as gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (type 2 DM). This study was approved by the local Ethical Committee. Forty-four women with GDM, 26 pregnant women with type 2 DM (diagnoses made according to WHO criteria w2x), and 69 normal pregnant women with similar maternal age and gestational age were consecutively recruited (Table 1) . A mid-stream urine specimen was collected once only from all women recruited for this study to reduce any known bias. In fact, a higher excretion of P-IPG was demonstrated well before the clinical onset of preeclampsia w5x. P-IPG content of urinary specimens was blindly assessed in triplicate using a polyclonal antibody-based ELISA as previously described w5x and corrected for urinary creatinine. Power analysis indicated a power of 0.96 with an alpha of 0.05 and a population standard deviation of 0.1.
Maternal BMI and birth weights were higher on average in the type 2 DM group than controls (P-0.01). Fasting plasma glucose was significantly higher in the GDM and type 2 DM groups than in controls (5.9"1.1 and 6.6"1.5 vs. 5.1"0.9 mmol/L, respectively, P-0.01). The urinary excretion of P-IPG was higher in women with GDM and type 2 DM compared with controls (Table 1 ; P-0.01). A positive trend in P-IPG excretion throughout pregnancy was found in the control group only (rs0.51, P-0.01). No association was found with 2 h postprandial glycemia. A higher release of P-IPG was found in diabetic subjects before 30 weeks' gestation compared to normal pregnancy (Figure 1 ), whereas the difference was lost in the third trimester, when insulin resistance is physiologically increased.
The development of a physiological insulin resistant state during pregnancy is considered to be a mechanism that allows a safe nutrient balance between the mother and the fetus. When this metabolic balance is disrupted, when a decreased maternal insulin sensitivity or increased insulin resistance exists, abnormalities of glucose *P-0.01, compared with controls. **P-0.01, type 2 diabetes mellitus (type 2 DM) vs. gestational diabetes mellitus (GDM).
Figure 1 P-IPG urinary excretion in the three study groups stratified by gestational age (Cscontrols, GDMsgestational diabetes mellitus, type 2 DMstype 2 diabetes mellitus). Values were divided into 5-week spans and reported as mean and standard error. P-IPG release was higher in GDM and type 2 DM groups between 21 and 30 weeks of gestation compared with controls (*P-0.05; **P-0.01).
metabolism become clinically evident (GDM or type 2 DM). The role of molecules with insulin-like characteristics stimulated the interest of many researchers. In diabetic subjects, a reduced P-IPG content in musclebiopsy and urinary specimens from insulin-resistant subjects was reported w1x, suggesting that P-IPG has an important role in mediating the effects of insulin on peripheral glucose utilization. Interestingly, we found a higher production/release of P-IPG in the second trimester in women with glucose tolerance abnormalities (GDM and type 2 DM) compared to healthy women. The comparison to non-pregnant insulin-resistant subjects seems to support the hypothesis of the fetal/placental unit as a potential source of P-IPG w4x which might partially restore insulin sensitivity and glucose disposal. In fact, Nestler and co-workers w3x reported that administration of chiro-inositol (P-IPG) increases insulin sensitivity in women with polycystic ovary syndrome, a disorder strongly associated with insulin resistance. The anabolic effect of P-IPG may explain the increased body fat and birth weight in fetuses from diabetic mothers compared to fetuses from normal pregnancies. Therefore, the fetal/placental unit seems not to have a simply permissive role in pregnancies with abnormal glucose metabolism; rather it adapts to the maternal environment and assumes an active role.
